Optimization of Radioimmunotherapy of Renal Cell Carcinoma: Labeling of Monoclonal Antibody cG250 with $^{131}$I, $^{90}$Y, $^{177}$Lu, or $^{186}$Re

Adrienne H. Brouwers, MD; Julliètte E.M. van Eerd, MSc; Cathelijne Frielink, MSc; Egbert Oosterwijk, PhD; Wim J.G. Oyen, MD, PhD; Frans H.M. Corstens, MD, PhD; and Otto C. Boerman, PhD

Department of Nuclear Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; and Department of Urology, University Medical Center Nijmegen, Nijmegen, The Netherlands

Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ($^{131}$I, $^{88}$Y/$^{90}$Y, $^{177}$Lu, and $^{186}$Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with subcutaneous renal cell cancer (RCC) tumors. Methods: The $^{88}$Y/$^{90}$Y and $^{177}$Lu labeling procedures of cG250 conjugated with cyclic diethylene triaminepentaacetic acid anhydride (cDTPA), isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), or 1,4,7,10-tetraazaacyclododecanetetraacetic acid (DOTA) were characterized. Stability of the labeled conjugates in plasma at 37°C was assessed. Biodistribution and therapeutic efficacy of labeled cG250 were compared in nude mice with SK-RCC-52 human RCC xenografts.

Results: Both SCN-Bz-DTPA and DOTA were stable in vitro (<5% release of the radiolabel during 14 and 21 d of incubation) and in vivo (uptake in bone ≤ 1.5 percentage injected dose per gram [%ID/g] at 7 d after injection) when used to label $^{88}$Y or $^{177}$Lu to cG250. The DOTA conjugate was slightly but significantly more stable than SCN-Bz-DTPA at 7 d after injection. In vivo, these cG250 preparations showed high tumor uptake (70 ± 15 %ID/g ± SD at 7 d after injection). Maximum tumor uptake for $^{125}$I-cG250 and $^{186}$Re-mercaptopoethylene-triglycine (MAG3)-cG250 (<20 ± 3 %ID/g ± SD) was reached at 3 d after injection and was much lower in comparison with cG250 labeled with the residualizing radionuclides. Because the highest specific activities could be prepared using SCN-Bz-DTPA, and relatively low protein doses of cG250 could be administered without saturating the tumor, cG250-SCN-Bz-DTPA conjugates were used in RIT studies. In RIT experiments at maximum tolerated dose, tumor growth was delayed most effectively by $^{177}$Lu, next most effectively by $^{90}$Y and $^{186}$Re (which were approximately equal), and least by $^{131}$I (delayed by approximately 185, 125, 90, and 25 d, respectively). The best median survival (300 d) was observed for $^{177}$Lu-SCN-Bz-DTPA-cG250. Median survival for control groups was <150 d. Conclusion: DOTA-conjugated radiolabeled antibodies were the most stable radioimmunoconjugates in vitro and in vivo as manifested by the lowest bone uptake. However, specific activity was higher for SCN-Bz-DTPA. The RIT studies clearly showed that the therapeutic efficacy of mAb cG250 labeled with $^{177}$Lu, $^{90}$Y, or $^{186}$Re was superior to that of $^{131}$I-cG250. The residualizing radionuclides $^{177}$Lu and $^{90}$Y led to higher radiation doses to the tumor and most likely are better candidates than conventionally radiolabeled $^{131}$I for RIT with cG250 in patients with RCC.

Key Words: renal cell carcinoma; monoclonal antibody cG250; experimental radioimmunotherapy; radionuclides; chelates
When released from the antibody, the metallic radionuclides $^{90}$Y and $^{177}$Lu are partly incorporated into the mineral bone (4), which may lead to excessive radiation to the bone marrow (5). To prevent in vivo dissociation of $^{90}$Y and $^{177}$Lu from the antibody, various chelates have been developed and tested both in vitro and in vivo. Initially, cyclic anhydride diethylenetriaminepentaacetic acid (cDTPA) was used to label mAbs with $^{90}$Y, because this chelate formed very stable complexes with $^{111}$In (6). However, mAbs labeled with $^{90}$Y via this chelate were unstable, leading to excessive accumulation of released $^{90}$Y in the bone (7–9). Therefore, bifunctional chelates based on DTPA (e.g., isothiocyanato-benzyl-DTPA [SCN-Bz-DTPA] and macrocyclic chelates such as 1,4,7,10-tetraazacyclododecane-1-tetraacetic acid [DOTA]) were developed for mAb-labeling purposes (7–10).

In addition to high stability and retained immunoreactivity after radiolabeling, the specific activity that can be obtained is also important in selecting a suitable chelate, especially in RIT of RCC with cG250. The most optimal protein dose for tumor targeting with cG250 is relatively low compared with other mAb-antigen systems. We have shown in patients with RCC that high uptake in the tumor (expressed as percentage injected dose per gram [%ID/g]) could be obtained only if the total cG250 protein dose per patient did not exceed 10 mg (1). For $^{90}$Y- or $^{177}$Lu-labeled antibodies in RIT in humans, one would aim to administer an activity dose of 1,110–2,220 MBq (30–60 mCi) $^{90}$Y or 5,550–7,400 MBq (150–200 mCi) $^{177}$Lu. This implies that for a protein dose of 5–10 mg, a specific activity $>370$ MBq/mg ($>10$ mCi/mg) is a prerequisite for RIT with cG250 in patients with RCC.

Another radionuclide that has become available for RIT is $^{186}$Re, with a $\beta$-particle range of 5 mm (Table 1). It has chemical properties similar to those of $^{90}$mTc, and the energy of the emitted $\gamma$-photons is similar as well. $^{186}$Re is therefore well suited for imaging with a $\gamma$-camera. As with $^{177}$Lu, the limited percentage of $\gamma$-emissions ($9\%$) of $^{186}$Re provides a major advantage from a radiation safety point of view, and the in vivo distribution of a therapeutic dose of $^{186}$Re-labeled antibody can be imaged scintigraphically. Several $^{186}$Re mAb-labeling methods have been described. The direct labeling method described by Griffiths et al. (11) results in low $^{186}$Re-to-mAb molar ratios, and the $^{186}$Re-mAb complex is unstable in vivo. The indirect labeling method described by Fritzberg et al. (12) and optimized by Visser et al. (13) using mercaptoacetyltriglycine (MAG3) as a chelate yielded relatively high $^{186}$Re-MAG3–to–mAb molar ratios, resulting in higher specific activities, and is suitable for RIT purposes. The $\beta$-emitter $^{188}$Re is less suited for RIT with IgG mAbs. The physical half-life (17 h) does not match with the relatively slow pharmacokinetics and tumor accretion of cG250 IgG (1).

To determine the most optimal radioimmunoconjugate to be labeled with mAb cG250 for RIT in humans, a series of experiments was designed. First, the in vitro and in vivo characteristics of cG250 labeled with $^{90}$Y and $^{177}$Lu using 3 different chelates (cDTPA, SCN-Bz-DTPA, and DOTA) were directly compared. The labeling efficiency, in vitro stability, and immunoreactivity of each of the labeled immunoconjugates were determined. Subsequently, the biodistribution of these radioimmunoconjugates was studied and compared with the biodistribution of $^{125}$I-cG250 and $^{186}$Re-MAG3-cG250 in nude mice with subcutaneous SK-RC-52 human RCC xenografts. Finally, the therapeutic efficacies of maximum tolerable activity doses (MTDs) of $^{90}$Y-SCN-Bz-DTPA-cG250, $^{177}$Lu-SCN-Bz-DTPA-cG250, $^{131}$I-cG250, and $^{186}$Re-MAG3-cG250 were studied.

### Table 1: Characteristics of Radionuclides

<table>
<thead>
<tr>
<th>Radionuclide</th>
<th>Half-life (days)</th>
<th>$E_{\text{max}}$ (MeV)</th>
<th>Abundancy</th>
<th>$E_{\gamma}$ (keV)</th>
<th>Abundancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{131}$I</td>
<td>8</td>
<td>0.6</td>
<td>89%</td>
<td>364</td>
<td>81%</td>
</tr>
<tr>
<td>$^{90}$Y</td>
<td>2.7</td>
<td>2.28</td>
<td>100%</td>
<td>208</td>
<td>11%</td>
</tr>
<tr>
<td>$^{177}$Lu</td>
<td>6.7</td>
<td>0.5</td>
<td>79%</td>
<td>113</td>
<td>6%</td>
</tr>
<tr>
<td>$^{186}$Re</td>
<td>3.8</td>
<td>1.08</td>
<td>71%</td>
<td>137</td>
<td>9%</td>
</tr>
</tbody>
</table>

The isolation and immunohistochemical reactivity of mAb G250 have been described elsewhere (1,14). To reduce the immunogenicity of the antibody, a chimeric version has been developed (15). mAb cG250 is reactive with the antigen G250 ($K_a = 4 \times 10^9$ L/mol), which has been identified as the tumor-associated isoenzyme carbonic anhydrase isoenzyme IX (MN/CA IX) (16). It is expressed on the cell surface of nearly all clear-cell RCCs and is absent on most other normal tissues and malignancies (1,14,17,18). The majority of RCCs (75%) are of the clear-cell type (14,16).

### Conjugation, Radiolabeling, and Quality Control

The conjugation of cDTPA (Fig. 1A) (Sigma) and SCN-Bz-DTPA (Fig. 1B) (Macrocyclics) to mAb cG250 was performed in a 0.1-mol/L NaHCO$_3$ buffer with pH 8.2 and using a 100-fold (cDTPA) or 50-fold (SCN-Bz-DTPA) molar excess, as described by Ruegg et al. (19) with minor modifications (conjugation period...
of 1 h at room temperature), cDTPA served as a reference for the 2 other immunoconjugates used (SCN-Bz-DTPA-cG250 and DOTA-cG250), because it is known that conjugation of cDTPA to mAbs leads to unstable radioimmunoconjugates when labeled with 90Y or 177Lu. The cDTPA-cG250 and SCN-Bz-DTPA-cG250 conjugates were labeled with either 88Y (Isotope Products Europe Blaseg) or 90Y (Perkin Elmer) or 177Lu (University of Missouri Research Reactor) in a 0.1 mol/L ammonium acetate buffer of pH 5.4 for 30 min at room temperature. For the in vitro stability tests and biodistribution experiments, the γ-emitter 88Y was substituted for 90Y. Similarly, 131I was used instead of 131I in the biodistribution experiments.

The activation and conjugation of DOTA (Fig. 1C) was performed as described by Lewis et al. (20). The DOTA-cG250 conjugate was labeled with either 88Y or 177Lu in an ammonium acetate buffer with pH 5.4 for 60 min at 45°C. The number of DOTA or DOTA ligands per cG250 molecule was determined as described by Hnatowich et al. (6).

MAb cG250 was radioiodinated with 125I (Amersham) and 131I (MDS Nordion) according to the IODO-GEN method (Pierce) for free and chelated radionuclides). All conjugation and labeling procedures using 177Lu or 88Y/90Y were performed under strict metal-free conditions. All radiolabeled cG250 preparations were purified by gel filtration on a PD-10 column (Amersham Pharmacia Biotech) and eluted with phosphate-buffered saline (PBS) supplemented with 0.5% bovine serum albumin (BSA). For all preparations, the amount of non-mAb-bound radiolabel was determined by instant thin-layer chromatography (ITLC) using ITLC silica gel strips (Gelman Sciences, Inc.), using 0.1 mol/L citrate buffer (pH 6.0) as the mobile phase (RF = 0 for radioimmunoconjugates, and RF = 0.8–1.0 for free and chelated radionuclides).

The immunoreactive fraction at infinite antigen excess of all radiolabeled cG250 conjugates was determined on freshly trypsinized SK-RC-52 RCC cells essentially as described by Lindmo et al. (22), with minor modifications (1).

**In Vitro Stability**

The stabilities of the various 88Y- and 177Lu-labeled preparations were assessed in vitro by diluting in plasma at an activity concentration of 18.5 kBq/mL (0.5 μCi/mL) for the 88Y preparations and 1,850 kBq/mL (50 μCi/mL) for the 177Lu preparations. A final concentration of 0.5 mmol/L ethylenediaminetetraacetic acid (EDTA) was added to capture released radiometal, and the preparations were incubated at 37°C. Plasma samples were analyzed at 0 and 4 h and at 1, 2, 5, 7, 9, 12, 15, 19, and 22 d by fast protein liquid chromatography (FPLC) using a Biosep Sec-S3000 gel filtration column (Phenomenex). In a previous study, we demonstrated that 131I-cG250 and 186Re-MAG3-cG250 were stable (<5% release of the radiolabel) in plasma up to 30 h using the same method (21).

**Nude Mouse Tumor Model**

The RCC cell line SK-RC-52 was derived from a mediastinal metastasis of a primary RCC and has been described elsewhere (23). SK-RC-52 cells were cultured in RPMI medium (Life Technologies) supplemented with 10% fetal calf serum (FCS) at 37°C in a humidified atmosphere with 5% CO2. Cells were washed in saline, trypsinized, and washed in RPMI + 10% FCS, and 2 × 106 cells (in 0.2 mL of RPMI medium) were injected subcutaneously into the right flank of 6- to 8-wk-old BALB/c nu/nu mice. Bio-distribution and RIT experiments were initiated 14–16 d after inoculation of tumor cells. All animal experiments were approved by the Animal Experiments Committee of the University Medical Center Nijmegen and performed in accordance with its guidelines.

**Biodistribution Experiments**

To study the biodistribution of the various 88Y-labeled immunoconjugates, RCC-tumor-bearing mice (median tumor weight, 0.08 g) were divided randomly into groups of 15 mice. Mice were injected intravenously with 37 kBq (1 μCi) 88Y-cDTPA-cG250 or 88Y-SCN-Bz-DTPA or 22.2 kBq (0.6 μCi) 88Y-DOTA-cG250, each diluted in PBS + 0.5% BSA. In a similar experiment, mice were injected intravenously with 185 kBq (5 μCi) 177Lu-cDTPA-cG250, 177Lu-SCN-Bz-DTPA-cG250, or 177Lu-DOTA-cG250. Also, 2 groups of 15 mice were injected intravenously with 185 kBq (5 μCi) 125I-cG250 or 1,850 kBq (50 μCi) 88Y-DOTA-cG250 (volume, 200 μL/mouse). In each group, 5 mice were killed at 1, 3, or 7 d after injection, and the biodistribution of the radiolabel was determined. The tumor and normal tissues (blood, muscle, femur without marrow, lung, spleen, kidney, liver, and small intestines without contents) were dissected, weighed, and counted in a γ-counter (Wizard; Pharmacia-LKB). To correct for radioactive decay, injection standards were counted simultaneously. The activity in samples was expressed as %ID/g tissue.

**Maximum Tolerated Dose**

The MTD of every radiolabeled cG250 preparation in mice was determined. BALB/c nu/nu mice (6–8 wk old, 5 per group) were injected intravenously with escalating doses of 131I-cG250 (7.4, 11.1, 14.8, 18.5, or 22.2 MBq [200, 300, 400, 500, or 600 μCi]), 90Y-SCN-Bz-DTPA-cG250 (2.8, 3.7, 4.6, 5.6, 6.5, 7.4, or 11.1 MBq [75, 100, 125, 150, 175, 200, or 300 μCi]), or 177Lu-SCN-Bz-DTPA-cG250 (19.4, 22.2, 25.9, or 29.6 MBq [525, 600, 700, or 800 μCi]). The MTD for 186Re-MAG3-cG250 was derived from...
similar experiments obtained with another intact IgG mAb used simultaneously at our department (9,3, 13.0, 18.5, or 24.1 MBq [250, 350, 500, or 650 μCi]). After injection, the mice were weighed and survival was monitored twice weekly during 2 mo. MTD was set 1 dose level below the dose level leading to >20% decrease in total body weight in at least 1 of the mice or early death of at least 1 mouse.

Dosimetry
Radiation dose estimates to the tumors of mice in the RIT experiments were determined by integrating the trapezoidal regions defined by the time–activity data from the biodistribution experiments. The resulting integral was converted to mGy/MBq using S values (MIRDOS3; unit density sphere model) appropriate for each radionuclide and assuming a tumor weight of 0.055 g, corresponding approximately to the mean tumor volume at the start of the RIT experiments (51 mm$^3$) (24). Mean absorbed dose in the tumor was further calculated by multiplying by the respective MTD of each radioimmunolabeled cG250 preparation. Absorbed dose in the tumor was calculated for $^{90}$Y using the $^{88}$Y biodistribution data and for $^{131}$I using the $^{125}$I biodistribution data.

Radioimmunotherapy Experiments
Based on the results of the radiolabeling and biodistribution studies, SCN-Bz-DTPA was selected instead of DOTA as a chelate for labeling $^{90}$Y and $^{177}$Lu to cG250 in subsequent RIT experiments. High specific activities, a necessity for RIT experiments with cG250 in humans, could be obtained with SCN-Bz-DTPA, and biodistribution experiments in mice showed only a slight advantage for the DOTA conjugates.

RIT studies were performed on nude mice (10 per group) with small (mean volume, 51 ± 5 mm$^3$) subcutaneous SK-RC-52 tumors. Mice received cG250 labeled with $^{131}$I, $^{90}$Y-SCN-Bz-DTPA, $^{177}$Lu-SCN-Bz-DTPA, or $^{186}$Re-MAG3 intravenously at MTD (protein doses of 30, 30, 60, and 35 μg per mouse, respectively). Mice in control groups received unlabeled cG250, PBS, or 5.6 MBq (150 μCi) $^{90}$Y-SCN-Bz-DTPA-cU36, the last serving as an irrelevant control mAb in this study (protein dose of 30 μg per mouse for the 2 cG250 groups) (25). In this tumor model, a cG250 antibody protein dose ≤ 60 μg was used to avoid a decrease of tumor uptake at higher protein doses as a result of saturation of accessible antigens in the tumor. In separate biodistribution studies in nude mice with subcutaneous SK-RC-52 tumors injected with variable protein doses of cG250 (3, 10, 30, 60, 90, 100, or 300 μg), only at protein doses ≥ 90 μg was cG250 uptake in RCC tumors decreased (unpublished data, 2003).

Tumor size was measured in 3 dimensions twice weekly with a caliper for the first 100 d and once each week thereafter. Tumor volume was used to calculate the mean tumor growth curve after injection of one of the preparations, then tumor growth delay was set at 0 d. This was the case in most mice in the control groups (unlabeled cG250, PBS, and $^{90}$Y-cU36). In the groups that received radioimmunolabeled cG250, most often a temporary maximum tumor volume was reached in the first 50 d after injection, expressed as $V_{\text{max}}$ on day $d_1$. In subsequent days, the tumor volume decreased, after which the tumor volume increased again. The day on which $V_{\text{max}}$ was reached for the second time was determined and designated as day $d_2$. The delay in exponential tumor growth was defined as and calculated by subtracting $d_1$ from $d_2$. For each group, mean and SD of exponential tumor growth delay were calculated.

Statistical Analysis
Statistical analysis of bone uptake in the biodistribution experiments was performed using Bonferroni-corrected, repeated-measures, 1-way ANOVA. The software package SPSS version 10.0 (SPSS Inc.) was used for statistical analysis of the RIT experiments. Because of lack of homogeneity of variances, the nonparametric procedure of Kruskal–Wallis was applied to look for significant differences in exponential tumor growth delay between the groups. Kaplan–Meier survival curves were analyzed for differences using the log-rank test. Differences were considered significant when $P < 0.05$ (2-sided).

RESULTS

Conjugation, Radiolabeling, and Quality Control
From 1 to 3 DTPA/DOTA moieties were conjugated per IgG molecule. Table 2 shows the maximum specific activity that could be obtained with each of the immunoconjugates. The maximum specific activity of the DOTA radioimmunoconjugates was approximately half the value that could be obtained with the dTPA-cG250 and SCN-Bz-DTPA-cG250 conjugates. The radiochemical purity after PD-10 purification was always >95%, except for the dTPA radioimmunoconjugates (Table 2). All preparations retained their immunoreactivity (Table 2).

Approximately 2 MAG3 moieties were conjugated per cG250 molecule. A specific activity of 518 kBq/μg (14 μCi/μg) was obtained for $^{186}$Re-MAG3-cG250 and 370 kBq/μg (10 μCi/μg) for $^{186}$Re-cG250. The immunoreactivity immediately after labeling was ≥95% for both $^{131}$I-cG250 and $^{186}$Re-MAG3-cG250 (Table 2).

In Vitro Stability
FPLC analysis of the preparations after incubation in human plasma indicated that all DOTA and SCN-Bz-DTPA preparations were quite stable, because <5% of the radiolabel was released during 14 d of incubation (Fig. 2). $^{88}$Y-DOTA-cG250 and $^{177}$Lu-DOTA-cG250 were even more stable, showing <5% release during the complete incubation period (22 d) (Fig. 2). As expected, both dTPA preparations were unstable in vitro, showing >10% release of the radiolabel in the first 24 h (Fig. 2).

Biodistribution Experiments
Biodistribution studies in nude mice with subcutaneous SK-RC-52 tumors showed relatively low blood levels for the $^{88}$Y-dTPA-cG250 preparation when compared with
88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-cG250, as a result of the known instability of the former preparation (blood levels of 1.5 %ID/g versus 8.4 %ID/g and 8.2 %ID/g at 7 d after injection, respectively) (Table 3). Conversely, bone uptake was much higher for 88Y-cDTPA–labeled cG250 than for 88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-cG250 (10.7 ± 0.2 %ID/g versus 1.2 ± 0.2 %ID/g and 0.4 ± 0.3 %ID/g at 7 d after injection, respectively) (Table 3). Although femur uptake was low for both 88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-cG250, indicating high stability of both radioimmunoconjugates, the difference became significant at 7 d after injection (P < 0.05). Both the 88Y-SCN-Bz-DTPA– and the 88Y-DOTA–labeled cG250 preparation showed high uptake in tumor (52 ± 7 %ID/g and 44 ± 15 %ID/g at 3 d after injection, with a further increase to 71 ± 8 %ID/g and 55 ± 11 %ID/g at 7 d after injection) (Fig. 3; Table 3). Uptake in other tissues at 7 d after injection was low and very similar for 88Y-SCN-Bz-DTPA-cG250 and 88Y-DOTA-cG250. The biodistributions of 177Lu-MAG3-cG250 and 125I-cG250 were nearly identical (Table 3).

Dosimetry

For the various preparations, mean absorbed doses in the tumors at MTD were estimated as 76 Gy for 131I-cG250, 95 Gy for 90Y-SCN-Bz-DTPA-cG250, 104 Gy for 186Re-MAG3-cG250, and 807 Gy for 177Lu-SCN-Bz-DTPA-cG250 (Table 4).

Radioimmunotherapy Experiments

The MTDs of the various labeled cG250 preparations were 11.1 MBq (300 μCi) for 131I-cG250, 5.6 MBq (150 μCi) for 90Y-SCN-Bz-DTPA-cG250, and 18.5 MBq (500 μCi) for both 177Lu-SCN-Bz-DTPA-cG250 and 186Re-MAG3-cG250. Within 10 d after intravenous injection of the various preparations at MTD, 2 mice died unexpectedly: one in the 177Lu group and another in the PBS control group. These deaths were not considered related to the injections, and these 2 mice were excluded from analysis. The survival curves (Fig. 4) show that the median survivals of the groups that received the corresponding 88Y-labeled cG250 immunoconjugates at 7 d after injection. However, uptake of 177Lu-SCN-Bz-DTPA-cG250 was significantly higher in normal tissues than was uptake of 177Lu-DOTA-cG250 at 7 d after injection (P < 0.0001). This phenomenon was not observed in the cG250 immunoconjugates labeled with 88Y (Table 3).

In contrast, uptake of 125I-cG250 was much lower in all tissues, especially in tumor (maximally 14 ± 3 %ID/g at 3 d after injection), whereas blood levels were similar compared with 88Y/177Lu-SCN-Bz-DTPA/DOTA-cG250, indicating a washout of the radioiodine label from the tumor (Table 3; Fig. 3).
Figures 5 and 6 show tumor growth curves of all individual mice, and Figure 7 shows the mean relative tumor growth per group. Individual mouse curves indicate that 

<table>
<thead>
<tr>
<th>Preparation</th>
<th>89Y-cDOTA</th>
<th>89Y-SCN-Bz-DTPA</th>
<th>89Y-DOTA</th>
<th>111Lu-cDOTA</th>
<th>111Lu-SCN-Bz-DTPA</th>
<th>177Lu-DOTA</th>
<th>125I</th>
<th>186Re-MAG3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor</td>
<td>32.9 ± 7.2</td>
<td>34.8 ± 8.5</td>
<td>36.2 ± 14.1</td>
<td>34.6 ± 10.8</td>
<td>53.2 ± 21.1</td>
<td>41.3 ± 9.9</td>
<td>11.7 ± 1.5</td>
<td>13.5 ± 1.8</td>
</tr>
<tr>
<td>Muscle</td>
<td>46.6 ± 19.7</td>
<td>51.9 ± 7.0</td>
<td>44.4 ± 14.8</td>
<td>59.0 ± 11.5</td>
<td>113.3 ± 24.7</td>
<td>86.9 ± 14.5</td>
<td>14.0 ± 3.0</td>
<td>16.9 ± 2.8</td>
</tr>
<tr>
<td>Blood</td>
<td>27.4 ± 4.8</td>
<td>70.9 ± 8.4</td>
<td>53.3 ± 10.7</td>
<td>45.0 ± 30.0</td>
<td>87.3 ± 14.0</td>
<td>74.5 ± 10.5</td>
<td>9.1 ± 2.0</td>
<td>7.9 ± 2.0</td>
</tr>
<tr>
<td>Femur</td>
<td>1.5 ± 0.2</td>
<td>8.4 ± 1.8</td>
<td>8.2 ± 1.9</td>
<td>1.6 ± 1.0</td>
<td>5.9 ± 1.7</td>
<td>6.0 ± 1.6</td>
<td>6.8 ± 1.6</td>
<td>6.7 ± 1.0</td>
</tr>
<tr>
<td>Spleen</td>
<td>6.3 ± 1.1</td>
<td>1.1 ± 0.5</td>
<td>0.7 ± 0.2</td>
<td>5.2 ± 1.2</td>
<td>1.3 ± 0.3</td>
<td>0.6 ± 0.2</td>
<td>0.7 ± 0.1</td>
<td>0.5 ± 0.2</td>
</tr>
<tr>
<td>Liver</td>
<td>3.7 ± 0.6</td>
<td>3.4 ± 0.6</td>
<td>2.7 ± 0.4</td>
<td>5.2 ± 2.0</td>
<td>5.5 ± 0.9</td>
<td>3.4 ± 0.5</td>
<td>2.9 ± 0.2</td>
<td>2.7 ± 0.4</td>
</tr>
<tr>
<td>Intestine</td>
<td>3.4 ± 0.9</td>
<td>2.9 ± 0.6</td>
<td>2.8 ± 0.3</td>
<td>4.2 ± 0.8</td>
<td>6.3 ± 1.5</td>
<td>3.2 ± 0.5</td>
<td>2.1 ± 0.4</td>
<td>2.6 ± 0.4</td>
</tr>
<tr>
<td>Kidney</td>
<td>7.1 ± 0.6</td>
<td>4.8 ± 0.6</td>
<td>4.8 ± 0.8</td>
<td>7.7 ± 0.5</td>
<td>6.7 ± 0.5</td>
<td>4.7 ± 0.4</td>
<td>4.4 ± 0.3</td>
<td>4.5 ± 0.2</td>
</tr>
<tr>
<td>Muscle</td>
<td>1.8 ± 0.3</td>
<td>1.4 ± 0.8</td>
<td>2.1 ± 0.4</td>
<td>2.2 ± 0.4</td>
<td>2.8 ± 0.8</td>
<td>1.9 ± 0.5</td>
<td>2.8 ± 0.5</td>
<td>2.5 ± 0.6</td>
</tr>
</tbody>
</table>

*Values given as %ID/g tissue ± SD.
Protein doses in the radiolabeled preparations were 50 μg each for 89Y-cDOTA, 89Y-DOTA, 89Y-SCN-Bz-DTPA, and 186Re-MAG3; 30 μg each for 111Lu-cDOTA, 111Lu-SCN-Bz-DTPA, and 177Lu-DOTA; and 16 μg for 125I.

The longest median delays of exponential tumor growth (Table 5). Mice in the 3 control groups did not show a statistically significant difference in exponential tumor growth delay (overall mean, approximately 8 d). In subsequent statistical analysis, therefore, mice in the 3 control groups were pooled. Treatment with 111Lu-SCN-Bz-DTPA-cG250 resulted in the longest delay in tumor growth (approximately 200 d). This was significantly longer than the delays observed with 90Y-SCN-Bz-DTPA-cG250 (P = 0.016) and 186Re-MAG3-cG250 (P < 0.001). The 90Y-labeled cG250 group did not differ significantly (P = 0.38) from the 186Re-labeled cG250 group in tumor growth delay (125 and 90 d, respectively). These 2 groups differed significantly (P < 0.001) from the group treated with 131I-cG250 (tumor growth delay of 27 d), which again differed significantly from the control groups (P < 0.001).

DISCUSSION

To directly compare the therapeutic efficacy of the cG250 antibody labeled with 131I, 90Y, 177Lu, or 186Re, we first determined the most suitable chelate and conjugation procedure for labeling the antibody with 89Y or 177Lu. The in vitro stability of DOTA was slightly better than that of SCN-Bz-DTPA, with the difference between the 2 conjugated.
gates becoming apparent only after >14 d incubation. However, in our study the higher stability of the DOTA-chelated radiometallic mAbs resulted in a significantly lower femur uptake compared with SCN-Bz-DTPA–chelated cG250 at 7 d after injection. This is in agreement with the results of Camera et al. (26), who reported virtually no release of $^{88}$Y from p-nitrobenzyl-DOTA (2B-DOTA) (0.5% ± 0.06%), whereas only a 5% release of activity was noted for 2DTPA-derivative chelates 2-(p-SCN-Bz)-cyclohexyl-DTPA (A isomer) and 2-(p-SCN-Bz)-6-methyl-DTPA after 17 d of incubation in serum. Nevertheless, in vivo this resulted in a significantly higher cortical bone uptake for the DTPA-derivative chelates than for DOTA (2.8 ± 0.2 %ID/g and 3.0 ± 0.3 %ID/g versus 1.2 ± 0.1 %ID/g at 7 d after injection, respectively) (26). Govindan et al. (27) reported a more marked difference in the in vitro stability of $^{90}$Y-DOTA and $^{90}$Y-Bz-DTPA, with a 0.4% versus 10.7% respective dissociation after 11 d incubation in serum. This also resulted in similar tumor and tissue uptake in nude mice bearing human B-cell lymphoma xenografts over a 10-d period, with the exception of bone uptake, which was up to 50% lower for $^{88}$Y-DOTA-hLL2 than for $^{88}$Y-Bz-DTPA-hLL2 (27). Whether DOTA is also superior for $^{177}$Lu has not been shown conclusively. Stein et al. (28) used DOTA as the chelate for facile and stable radiolabeling of mAb RS7 with $^{177}$Lu and $^{88}$Y and observed nearly identical biodistribution results for the radionuclides as did we when using DOTA as the chelate.

We used the same considerations as Milenic et al. (10) when we proceeded with the immunonoconjugate SCN-Bz-DTPA-cG250 for RIT of RCC. Because higher specific activities could be obtained with the SCN-Bz-DTPA-cG250 conjugate, we used this immunonoconjugate for subsequent RIT experiments in nude mice with subcutaneous RCC tumors. When labeling DOTA conjugates with $^{90}$Y or $^{177}$Lu, traces of metal ions competing for complexation with DOTA apparently limit the maximum specific activity that can be obtained. So far, the requirement of a high specific activity (>10 mCi/mg) could be met only when derivatized DTPA was used as a chelate.

**FIGURE 4.** Survival curves of groups treated at MTD ($^{131}$I-cG250, $^{186}$Re-MAG3-cG250, $^{90}$Y-ITC-Bz-DTPA-cG250, and $^{177}$Lu-ITC-Bz-DTPA-cG250 groups), and controls (unlabeled cG250, PBS, and 5.6 MBq [150 mCi] $^{90}$Y-cU36 groups).

**TABLE 4**

<table>
<thead>
<tr>
<th>Radioimmunoconjugate preparation</th>
<th>Self-dose S value* (mGy/MBq · s)</th>
<th>AUC (h)</th>
<th>Absorbed tumor dose (Gy)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{131}$I-cG250</td>
<td>1.305</td>
<td>29.16</td>
<td>76</td>
</tr>
<tr>
<td>$^{186}$Re-MAG3-cG250</td>
<td>1.9215</td>
<td>16.30</td>
<td>104</td>
</tr>
<tr>
<td>$^{90}$Y-SCN-Bz-DTPA-cG250</td>
<td>2.055</td>
<td>46.17</td>
<td>95</td>
</tr>
<tr>
<td>$^{177}$Lu-SCN-Bz-DTPA-cG250</td>
<td>1.2035</td>
<td>201.44</td>
<td>807</td>
</tr>
</tbody>
</table>

*For tumors of 0.055 g (MIRDose3, unit density sphere model) (24).

AUC = area under the curve.
clides was approximately 4 times higher than tumor uptake obtained with radioiodinated cG250. Numerous studies have demonstrated that the enhanced uptake of radionuclides such as $^{111}$In and $^{90}$Y is the result of intracellular retention of the radiolabeled catabolites after internalization of the radiolabeled antibody (29–32). In contrast, the lysosomal degradation product of radioiodinated mAbs, $^{131}$I-tyrosine, is released from the target cell (29,31). As a result of the longer retention time of residualizing radionuclides in the tumor, higher radiation doses to the tumor are achieved, leading to an enhanced antitumor effect (29,33,34). Various radioiodination methods have now been developed that improve the intracellular retention of the iodine label in the target cell (29,31,32,35,36). It might be worthwhile to consider these methods for labeling cG250 with $^{131}$I. However, the physical disadvantages of $^{131}$I, including relatively long half-life and high-energy γ-photons, would still remain.

The intracellular effect of a $^{186}$Re-MAG3–labeled mAb on cell binding and internalization still needs to be elucidated. According to our observations in the biodistribution experiments, $^{186}$Re-MAG3-cG250 showed a pattern nearly identical to that of $^{131}$I-cG250, resulting in low tumor accretion and more rapid washout of the radiolabeled antibody preparation from the tumor (maximum tumor uptake, 17 %ID/g at 3 d after injection), which is similar to earlier results (21,37). Nevertheless, the results of the RIT experiments did show a difference in these 2 preparations. Although $^{131}$I-cG250 showed a significantly shorter delay in tumor growth compared with $^{90}$Y- and $^{177}$Lu-labeled cG250, $^{186}$Re-MAG3-cG250 performed as well as $^{90}$Y-SCN-Bz-DTPA-cG250 (no significant difference) and significantly outperformed $^{131}$I-cG250. This is in line with the results of Kievit et al. (37), who reported similar biodistribution results for $^{186}$Re- and $^{131}$I-labeled mAb 323/A3 that resulted in a 1.3-fold higher cumulative absorbed radiation dose in the tumor for $^{186}$Re-labeled-323/A3. When mice were treated with equivalent radionuclide doses, tumor growth inhibition was also slightly better for the group injected with $^{186}$Re-labeled 323/A3 (37). Because in our RIT experiments the MTD of $^{186}$Re-cG250 was considerably higher than that of $^{131}$I-cG250, this might explain the observed pronounced differences in tumor growth delay between mice treated with $^{186}$Re-labeled and radioiodinated cG250.

Comparison of the RIT results of the current study with data from published literature on similar RIT experiments in nude mice is difficult, because experimental settings may differ widely (e.g., different sizes of tumor volume treated or various methods to dose the radiolabeled mAb). Second, the doses used for RIT can be based on established MTDs,
equivalent radionuclide doses, or even doses adjusted to deliver equal cumulative absorbed radiation doses to the tumor (28,34,37,38).

Although dosimetric calculations to estimate the absorbed radiation dose in the tumors can be fairly inaccurate as a result of the inaccuracy of the models used, the relative observed delays in tumor growth in the treatment groups (177Lu was longer than 90Y, which was approximately equal to 186Re, which was longer than 131I) corresponded to the respective calculated estimates of radiation-absorbed dose in the tumors (177Lu was greater than 186Re, which was greater than 90Y, which was greater than 131I).

The fact that the residualizing radionuclides 90Y and 177Lu when labeled to mAbs performed much better than conventionally radiolabeled mAbs has also been demonstrated previously (33,34). However, unlike Stein et al. (28), who

### TABLE 5

<table>
<thead>
<tr>
<th>Radioimmunoconjugate preparation</th>
<th>Mean exponential tumor growth delay (d ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlabeled cG250</td>
<td>7.9 ± 4.1</td>
</tr>
<tr>
<td>PBS</td>
<td>6.0 ± 5.0</td>
</tr>
<tr>
<td>90Y-SCN-Bz-DTPA-cU36</td>
<td>9.6 ± 4.4</td>
</tr>
<tr>
<td>131I-cG250</td>
<td>26.6 ± 10.2</td>
</tr>
<tr>
<td>90Y-SCN-Bz-DTPA</td>
<td>124.5 ± 69.1</td>
</tr>
<tr>
<td>186Re-MAG3</td>
<td>90.0 ± 30.5</td>
</tr>
<tr>
<td>177Lu-SCN-Bz-DTPA</td>
<td>186.4 ± 34.7</td>
</tr>
</tbody>
</table>
did not find a marked difference in biodistribution and therapeutic efficacy between 90Y- and 177Lu-labeled mAb RS7 in a direct comparison, our RIT experiments showed that 177Lu-SCN-Bz-DTPA-cG250 was superior even to 90Y-SCN-Bz-DTPA-cG250. This could be explained in part by the small size of the tumors used in the current experiments when compared with the large, established tumors (mean tumor volume, 0.85 cm²) in the RIT experiments performed by Stein et al. (28). The smaller size of the tumor volumes would be to the advantage of 177Lu as compared with 90Y, the former being the β-emitter with the lowest energy and, therefore, better suited to irradiate small tumors. Siegel et al. (39) and O’Donoghue et al. (40) calculated that in small tumors a relatively large portion of the emitted energy of 90Y is deposited outside the tumor, compared with radionuclides with a lower-energy β-emission, such as 131I or 177Lu. Recently, De Jong et al. (3) showed that 90Y-DOTA-TYR₃-octreotide was able to induce tumor regression in rats, especially in tumors of medium size (3–9 cm³). However, in small tumors (<1 cm³), this effect was less pronounced. In contrast, the growth of small tumors (<1 cm³) could be prevented effectively with an identical radiation dose (60 Gy) to the tumor with 177Lu-DOTA-TYR₃-octreotate, nicely providing experimental evidence for this theory (38). In addition, the half-life of 177Lu is better suited for the relatively slow pharmacokinetics of radiolabeled whole-IgG antibody. Blood clearance and tumor uptake of radiolabeled cG250 are slow, and thus a higher tumor dose is obtained with 177Lu than with 90Y.

We recently demonstrated that cG250 labeled with re- sidualizing radionuclides had a higher uptake in RCC lesions in humans than does conventionally radioiodinated cG250 (41). Depending on the size of the lesions at which treatment is aimed (macroscopic metastases, microscopic or small-volume disease, or in an adjuvant setting), RIT with cG250 labeled with 90Y or 177Lu may have an impact in patients with RCC.

CONCLUSION

These experimental RIT studies clearly showed that the therapeutic efficacies of the cG250 preparations labeled with 177Lu, 90Y and 186Re are superior to that of 131I-cG250. 177Lu showed the best antitumor effect, most likely as a result of optimal radiation characteristics for small tumors and a physical half-life that better matches mAb pharmacokinetics. The present study shows that especially the residualizing radionuclides 90Y and 177Lu are potentially better candidates for RIT studies in patients with RCC than is conventionally radiolabeled 131I using mAb cG250.

ACKNOWLEDGMENTS

Ton Feuth, Department of Epidemiology and Biostatistics, University Medical Center (UMC) Nijmegen, is gratefully acknowledged for his advice on statistical analysis. Wil Buijs, PhD (Department of Nuclear Medicine, UMC Nijmegen), performed the dosimetric calculations. The authors thank Gerry Grutters, Bianca Lemmers, and Henrie Eikholts of the Central Animal Laboratory, UMC Nijmegen, for excellent technical assistance. The Dutch Cancer Society supported this work through grant number KUN99-1973. Egbert Oosterwijk, PhD, is supported by the Ludwig Institute for Cancer Research, New York, NY.

REFERENCES


